{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:54:16Z","timestamp":1790013256996,"version":"4.0.1"},"reference-count":4,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jaad.2013.10.054","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T09:12:34Z","timestamp":1389777154000},"page":"e37-e38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%"],"prefix":"10.1016","volume":"70","author":[{"given":"Ethan T.","family":"Routt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob O.","family":"Levitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.10.054_bib1","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema a of rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2013.10.054_bib2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1517\/14740331003709736","article-title":"Brimonidine for glaucoma","volume":"9","author":"Rhaman","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaad.2013.10.054_bib3","unstructured":"Galderma Laboratories LP. Mirvaso (brimondine) 0.33% topical gel package insert. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204708lbl.pdf."},{"key":"10.1016\/j.jaad.2013.10.054_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.anorl.2012.09.005","article-title":"Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel","volume":"130","author":"Mortuaire","year":"2013","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213011778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213011778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:30:46Z","timestamp":1759271446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213011778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":4,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0190962213011778"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.10.054","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.10.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}